In human pregnancy, fetally derived extravillous trophoblasts invade the uterine wall and remodel the maternal spiral arteries into dilated, low-resistance vessels; failure of this remodeling underlies early-onset preeclampsia and intrauterine growth restriction. Kadyrov, Kingdom and Huppertz (AJOG 2006) showed with full-thickness placental bed specimens that trophoblast invasion is severely reduced and intramural trophoblast apoptosis roughly doubled in early-onset preeclampsia/IUGR, whereas in chronic maternal anemia invasion is increased without excess apoptosis — a divergent phenotype whose causes remain unexplained. The open problem is to identify the upstream mechanisms and cellular mediators that produce this divergence, to weigh early trophoblast proliferation deficits against increased apoptosis, to delineate the first-trimester temporal sequence of remodeling events and how it diverges between the two conditions, to separate disease effects from gestational-age effects, and to determine whether modulating proliferation or apoptosis pathways can restore normal remodeling. Each of these facets remains open in humans in situ.

Background

Preeclampsia (PE) is a pregnancy-specific syndrome defined by new-onset hypertension with proteinuria or other organ dysfunction after 20 weeks' gestation; the early-onset form (delivery before ~34 weeks) is strongly associated with fetal growth restriction (intrauterine growth restriction, IUGR — failure of the fetus to achieve its growth potential) and with defective placentation. Successful human placentation depends on physiological transformation of the uterine spiral arteries: extravillous trophoblasts (EVTs) — fetal cells that leave the placental villi and invade the uterine wall (the placental bed) — replace the endothelium and smooth muscle of these maternal vessels with fibrinoid (an acellular hyaline matrix material) and trophoblast, converting narrow muscular arteries into wide, compliant vessels that supply the intervillous space (the compartment of the placenta where maternal blood circulates around the fetal villi). This transformation proceeds through the first half of pregnancy in temporally ordered stages (decidual immune-cell association, interstitial and endovascular trophoblast invasion, vessel occlusion by trophoblast plugs, and later plug loosening and dilation), classically described as a two-wave invasion process. In early-onset PE/IUGR the transformation is incomplete: invasion is shallow, vessels stay narrow, and the placenta becomes hypoperfused. Apoptosis — programmed cell death executed by caspases (intracellular proteases that dismantle the cell) — is a normal feature of trophoblast turnover, and a family of markers (e.g. the M30 antibody recognizing a caspase-cleaved cytokeratin-18 neoepitope) allows its quantification in tissue sections. Kadyrov, Kingdom and Huppertz (Am J Obstet Gynecol 2006;194:557-563) quantified invasion and apoptosis in full-thickness uterine wall samples (a specimen type obtainable essentially only at hysterectomy or specific delivery circumstances) from normal pregnancies, chronic maternal anemia, and early-onset PE/IUGR. They found intramural invasion — trophoblast cell profiles within the spiral artery wall, as distinct from endovascular trophoblast lining or plugging the vessel lumen, and labeled by cytokeratin (an epithelial cytoskeletal marker used to identify trophoblasts) — of 206, 149, and 17 cell profiles per mm² in anemia, normal, and PE/IUGR respectively, with trophoblast apoptosis of 4.2%, 5.0%, and 12%: invasion in early-onset PE/IUGR is limited by increased intramural apoptosis, while anemia shows enhanced, apoptosis-sparing invasion. A mechanistic scaffold already existed: the same group had shown in vitro (Reister et al., Lab Invest 2001) that activated decidual macrophages — immune cells abundant in the preeclamptic placental bed — can kill EVTs via combined tumor necrosis factor alpha (TNFα, a macrophage-derived cytokine binding death receptors) signaling and tryptophan depletion (local depletion of the essential amino acid tryptophan, e.g. through the catabolic enzyme indoleamine 2,3-dioxygenase), while noting that what activates and recruits these macrophages is unknown. Uterine natural killer (uNK) cells, decidual macrophage polarization (M1/pro-inflammatory vs M2/tolerogenic states), oxygen tension, and maternal metabolic and angiogenic factors have all since been implicated in remodeling, but the initiating lesion and the causal chain leading to excess trophoblast apoptosis in early-onset PE remain unsettled — a point made explicitly by reviews as recent as 2022–2026, some of which now question whether the classical second-trimester spiral-artery-failure framework locates the initiating lesion correctly at all. The morphometric comparison itself leaves five unresolved issues that jointly define the open problem: (1) the preeclamptic group delivered earlier than controls, and gestational-age-matched full-thickness controls are effectively unobtainable, so gestational age versus disease cannot be fully separated in these specimens; (2) the relative contributions of reduced early trophoblast proliferation versus increased apoptosis to the final low trophoblast numbers were not quantified; (3) the upstream mechanisms and cellular mediators inducing the excess apoptosis were not established by the morphometric data; (4) the first-trimester temporal sequence of remodeling events, and how it diverges in anemia versus preeclampsia, cannot be resolved by cross-sectional delivered specimens; and (5) whether the apoptosis/proliferation balance can be therapeutically modulated to restore normal remodeling remains untested. These facets share one scientific objective: a causal, temporally resolved account of the divergent placental bed phenotypes, not merely a description of either condition in isolation.

Problem Statement

The problem left open by the findings of Kadyrov, Kingdom and Huppertz (2006) is to explain the divergent placental bed phenotypes of early-onset preeclampsia/intrauterine growth restriction (PE/IUGR) and chronic maternal anemia at a causal, mechanistic level. Specifically: (1) identify the upstream mechanisms and cellular mediators (including the role, activation state, and signals of maternal macrophages and other decidual immune cells) that induce the increased intramural and endovascular trophoblast apoptosis and severely impaired spiral artery remodeling of early-onset PE/IUGR, while sparing the anemic placental bed, where invasion is enhanced without excess apoptosis; (2) determine the relative contributions of altered trophoblast proliferation early in pregnancy versus increased apoptosis to the final intramural/endovascular trophoblast numbers in each condition; (3) delineate the first-trimester temporal sequence of spiral artery remodeling events — emergence of the endovascular trophoblast phenotype, vessel occlusion and plug loosening, dilation, and immune-cell interactions — and establish where and how this sequence diverges in anemia versus preeclampsia; (4) disentangle gestational-age effects from disease effects, which requires resolving the absence of gestational-age-matched full-thickness placental bed controls; and (5) determine whether modulating the trophoblast apoptosis/proliferation balance can restore normal spiral artery remodeling, and test this experimentally and clinically. The five facets are jointly to be addressed, under one acceptance standard: each is resolved by the best-supported inference from existing human, archival, and model-system evidence and, where the requisite in-situ measurement does not exist, by the measurement or study design that would settle it — how early proliferation can be weighted against apoptosis, how the divergent first-trimester sequence can be measured, how the gestational-age confound can be resolved, and what experimental or clinical design would test modulation of the apoptosis/proliferation balance — rather than by obtaining new specimens or running new trials. These facets jointly support one objective: a causal, temporally resolved account of why trophoblast invasion fails in early-onset PE/IUGR yet is amplified in anemia, addressing the divergence between the two conditions rather than either condition in isolation.

References

  1. Kadyrov M, Kingdom JCP, Huppertz B. Divergent trophoblast invasion and apoptosis in placental bed spiral arteries from pregnancies complicated by maternal anemia and early-onset preeclampsia/intrauterine growth restriction. Am J Obstet Gynecol. 2006;194(2):557-563. doi:10.1016/j.ajog.2005.07.035. https://doi.org/10.1016/j.ajog.2005.07.035 (PubMed PMID 16458661)
  2. Reister F, Frank HG, Kingdom JC, Heyl W, Kaufmann P, Rath W, Huppertz B. Macrophage-induced apoptosis limits endovascular trophoblast invasion in the uterine wall of preeclamptic women. Lab Invest. 2001;81(8):1143-1152. doi:10.1038/labinvest.3780326. https://doi.org/10.1038/labinvest.3780326
  3. Naicker T, Dorsamy E, Ramsuran D, Burton GJ, Moodley J. The role of apoptosis on trophoblast cell invasion in the placental bed of normotensive and preeclamptic pregnancies. Hypertens Pregnancy. 2013;32(3):245-256. doi:10.3109/10641955.2013.796969. https://doi.org/10.3109/10641955.2013.796969
  4. Dagdelen M, Temur M, Yılmaz Ö, Altındag T, Uslu T, Özbay PÖ. Placental bed apoptosis is increased in pregnant women with pre-eclampsia versus normotensive pregnant women. J Obstet Gynaecol. 2016;36(8):974-979. doi:10.1080/01443615.2016.1178221. https://doi.org/10.1080/01443615.2016.1178221
  5. Staff AC, Fjeldstad HE, Fosheim IK, Moe K, Turowski G, Johnsen GM, Alnaes-Katjavivi P, Sugulle M. Failure of physiological transformation and spiral artery atherosis: their roles in preeclampsia. Am J Obstet Gynecol. 2022;226(2S):S895-S906. doi:10.1016/j.ajog.2020.09.026. https://doi.org/10.1016/j.ajog.2020.09.026
  6. Boulanger H, Bounan S, Mahdhi A, Drouin D, Ahriz-Saksi S, Guimiot F, Rouas-Freiss N. Immunologic aspects of preeclampsia. AJOG Glob Rep. 2024;4(1):100321. doi:10.1016/j.xagr.2024.100321. https://doi.org/10.1016/j.xagr.2024.100321
  7. Torres-Torres J, Espino-Y-Sosa S, Martinez-Portilla R, Borboa-Olivares H, Estrada-Gutierrez G, Acevedo-Gallegos S, Ruiz-Ramirez E, Velasco-Espin M, Cerda-Flores P, Ramirez-Gonzalez A, Rojas-Zepeda L. A Narrative Review on the Pathophysiology of Preeclampsia. Int J Mol Sci. 2024;25(14):7569. doi:10.3390/ijms25147569. https://doi.org/10.3390/ijms25147569
  8. Greenbaum S, Averbukh I, Soon E, Rizzuto G, Baranski A, Greenwald NF, Kagel A, Bosse M, Jaswa EG, Khair Z, Kwok S, Warshawsky S, Piyadasa H, Goldston M, Spence A, Miller G, Schwartz M, Graf W, Van Valen D, Winn VD, Hollmann T, Keren L, van de Rijn M, Angelo M. A spatially resolved timeline of the human maternal-fetal interface. Nature. 2023;619(7970):595-605. doi:10.1038/s41586-023-06298-9. https://doi.org/10.1038/s41586-023-06298-9
  9. Ye S, Ma Y, Li W, Qi L, Fang X, Yu X, Yu D, Wang X, Chen DB, Wang YL. Dynamic spiral artery remodeling in early human pregnancy: an analysis of specimens collected with a standardized protocol. Biol Reprod. 2026;114(4):1445-1457. doi:10.1093/biolre/ioaf279. https://doi.org/10.1093/biolre/ioaf279 (online first 2025-12-16)
  10. Rolnik DL, Wright D, Poon LC, O'Gorman N, Syngelaki A, de Paco Matallana C, Akolekar R, Cicero S, Janga D, Singh M, Molina FS, Persico N, Jani JC, Plasencia W, Papaioannou G, Tenenbaum-Gavish K, Meiri H, Gizurarson S, Maclagan K, Nicolaides KH. Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia. N Engl J Med. 2017;377(7):613-622. doi:10.1056/NEJMoa1704559. https://doi.org/10.1056/NEJMoa1704559
  11. Rolnik DL, Syngelaki A, O'Gorman N, Wright D, Nicolaides KH, Poon LC. Aspirin for evidence-based preeclampsia prevention trial: effects of aspirin on maternal serum pregnancy-associated plasma protein A and placental growth factor trajectories in pregnancy. Am J Obstet Gynecol. 2024;231(3):342.e1-342.e9. doi:10.1016/j.ajog.2023.12.031. https://doi.org/10.1016/j.ajog.2023.12.031
  12. Li L, Lu X, Lian Q, Wang X, Jia C, Xu C. Apoptotic vesicles of mesenchymal stem cells promote M2 polarization and alleviate early-onset preeclampsia via miR-191-5p. Stem Cell Res Ther. 2025;16(1):414. doi:10.1186/s13287-025-04546-5. https://doi.org/10.1186/s13287-025-04546-5
  13. Bilginer C, Çetin A. Rethinking preeclampsia: six paradigm shifts in placental pathophysiology for maternal-foetal medicine. Front Med (Lausanne). 2026;13:1874122. doi:10.3389/fmed.2026.1874122. https://doi.org/10.3389/fmed.2026.1874122